Leukemia

user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:73e17bcc1a94ebd672b913e6684b1727' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: Palifermin may help relieve or prevent oral mucositis caused by chemotherapy and radiation therapy in young patients undergoing stem cell transplant. PURPOSE: This randomized phase II trial is studying palifermin to see how well it works compared with a placebo in preventing oral mucositis caused by chemotherapy and/or radiation therapy in young patients undergoing stem cell transplant.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:73e17bcc1a94ebd672b913e6684b1727' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:df5f8ae469adb8470aa30e5df7c98a46' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'A Group-Wide Double-Blind Randomized Placebo-Controlled Trial of Palifermin to Prevent Chemotherapy and/or Radiotherapy Induced Oral Mucositis in Children Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:df5f8ae469adb8470aa30e5df7c98a46' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a35da0cfa0a7a86f6409af67c4b7bd98' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'OBJECTIVES: Primary\n<ul>\n<li>To compare whether palifermin versus placebo administered to pediatric patients three days prior to conditioning and three days after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) is associated with a reduction in the incidence of WHO grade 3 or 4 oral mucositis.</li>\n</ul>\n Secondary\n<ul>\n<li>To evaluate the safety and tolerability of palifermin.</li>\n<li>To evaluate the long-term effects of palifermin on disease outcome and survival.</li>\n<li>To compare the incidence, total dose, and duration of parenteral opioid analgesic use (morphine equivalents), and incidence and duration of total parenteral nutrition (TPN) administration in patients treated with these regimens.</li>\n<li>To compare the incidence of febrile neutropenia and invasive bacterial infections in patients treated with these regimens.</li>\n<li>To determine whether palifermin versus placebo reduces the incidence of WHO grade 3 or 4 oral mucositis among allogeneic HSCT pediatric patients receiving methotrexate as graft-versus-host disease (GVHD) prophylaxis.</li>\n<li>To determine whether palifermin versus placebo reduces acute and chronic GVHD after allogeneic HSCT.</li>\n<li>To describe health care utilization (hospitalization duration, and administration of antibiotics, TPN, nasogastric-, nasojejunal- or gastrostomy-administered enteral nutrition, and blood products) in pediatric patients treated with these regimens.</li>\n</ul>\n OUTLINE: This is a multicenter study. Patients are stratified according to age in years (1 to 2 vs 3 to 11 vs 12 to 16), type of hematopoietic stem cell transplantation (HSCT) (autologous vs allogeneic), conditioning regimen (either total-body irradiation [TBI] or melphalan vs neither TBI nor melphalan). Patients are randomized to 1 of 2 treatment arms.\n<ul>\n<li>Arm I: Patients receive palifermin IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity.</li>\n</ul>\n Patients then receive palifermin IV on days 0, 1, and 2 after autologous or allogeneic HSCT.\n<ul>\n<li>Arm II: Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic HSCT.</li>\n</ul>\n Blood samples are collected at baseline, 32 days, and 100 days after HSCT to evaluate the immunogenicity of palifermin. Oral mucositis is assessed at baseline, daily for 8 days prior to and 32 days after HSCT, or until oral mucositis has resolved by the WHO Mucositis Scale, Oral Mucositis Assessment Scale (OMAS), modified Walsh mucositis scale, Oral Mucositis Daily Questionnaire (OMDQ), and the pain categorical rating scale. After completion of HSCT, patients are followed periodically for up to 10 years.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a35da0cfa0a7a86f6409af67c4b7bd98' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:bb95235845e20e6a675762a6d3f40d7e' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'DISEASE CHARACTERISTICS:\n<ul>\n<li>Patients undergoing myeloablative autologous or allogeneic hematopoietic stem cell transplantation (HSCT) for any indication</li>\n<li>Any type of myeloablative HSCT conditioning regimen allowed</li>\n<li>Patients undergoing allogeneic HSCT may undergo 1 of the following types of donor stem cells:\n<ul>\n<li>HLA-matched sibling or parent</li>\n<li>Partially matched family donor (mismatched for a single HLA locus [class I])</li>\n<li>Fully matched unrelated marrow or peripheral blood stem cell donor</li>\n<li>HLA-matched or partially mismatched (at least 4 of 6 match) cord blood (class I or II)</li>\n</ul>\n</li>\n</ul>\n PATIENT CHARACTERISTICS:\n<ul>\n<li>Not pregnant or nursing</li>\n<li>Negative pregnancy test</li>\n<li>Fertile patients must use effective contraception</li>\n<li>No HIV positivity</li>\n<li>No known sensitivity to any E. coli-derived products\n<ul>\n<li>Known grade 1 to 2 allergic reactions to asparaginase allowed</li>\n<li>No prior grade 3-4 allergies to asparaginase or pegaspargase</li>\n</ul>\n</li>\n</ul>\n PRIOR CONCURRENT THERAPY:\n<ul>\n<li>See Disease Characteristics</li>\n<li>More than 30 days since prior and no concurrent treatment with any of the following therapies:\n<ul>\n<li>Oral cryotherapy</li>\n<li>Glutamine as an oral supplement</li>\n<li>Traumeel®</li>\n<li>Gelclair®</li>\n<li>Oral vancomycin paste</li>\n<li>Low-level laser therapy</li>\n<li>An investigational product or device in another clinical trial</li>\n</ul>\n</li>\n<li>No prior palifermin or other keratinocyte growth factors</li>\n<li>No other concurrent cytotoxic drugs for conditioning or graft-vs-host disease prophylaxis\n<ul>\n<li>Intrathecal methotrexate or cytarabine for CNS involvement allowed</li>\n</ul>\n</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:bb95235845e20e6a675762a6d3f40d7e' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:ec6dbdc887d16cd51563c4748d35fa7e' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Safety and tolerability of palifermin [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:ec6dbdc887d16cd51563c4748d35fa7e' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:8eebff6f10ca6c1fd499b9e8948d715b' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Long-term disease outcome and survival [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:8eebff6f10ca6c1fd499b9e8948d715b' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:0ba2af343f300b31fc7e925de958cb39' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Duration of WHO grade 3 or 4 oral mucositis [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:0ba2af343f300b31fc7e925de958cb39' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:efda079bce71216266982e184ec19e9c' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence, total dose, and duration of parenteral opioid analgesic use (morphine equivalents) [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:efda079bce71216266982e184ec19e9c' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:02fac6ce9cae062f7b8ef9c212258471' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence and duration of total parenteral nutrition administration [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:02fac6ce9cae062f7b8ef9c212258471' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:9e8fe591e820bb46408a222bc02fcaff' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of febrile neutropenia and invasive bacterial infections [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:9e8fe591e820bb46408a222bc02fcaff' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a24c53e1e9c2beb430185cc3a2a2a849' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of WHO grade 3 or 4 oral mucositis among allogeneic HSCT patients receiving methotrexate as GVHD prophylaxis [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a24c53e1e9c2beb430185cc3a2a2a849' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:4d84bcb8e25523003f9e0c8a53ba6cfa' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of acute and chronic GVHD after allogeneic HSCT [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:4d84bcb8e25523003f9e0c8a53ba6cfa' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:691942a1d6e9235aa1fe7f2d68315455' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Health care utilization [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:691942a1d6e9235aa1fe7f2d68315455' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:718f3a90213cad334b1b9a402c9779f3' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with fludarabine and cyclophosphamide may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with fludarabine and cyclophosphamide and to see how well they work in treating patients with advanced chronic lymphocytic leukemia that did not respond to previous therapy.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:718f3a90213cad334b1b9a402c9779f3' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:529f4265c40e82c6795fbbebd13318c4' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:529f4265c40e82c6795fbbebd13318c4' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:b547e4a4a64449564310e07702ad85e1' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'OBJECTIVES: Primary\n<ul>\n<li>To determine the maximum tolerated dose (MTD) of lenalidomide when administered with fludarabine and cyclophosphamide in patients with advanced relapsed or refractory chronic lymphocytic leukemia. (Phase I)</li>\n<li>To evaluate the complete response (CR) rate in patients treated with lenalidomide (at the MTD) in combination with fludarabine and cyclophosphamide.</li>\n</ul>\n (Phase II) Secondary\n<ul>\n<li>To evaluate the CR rate in patients treated with this regimen. (Phase I)</li>\n<li>To determine the toxicity of this regimen in these patients.</li>\n<li>To determine the infection rate in patients treated with this regimen.</li>\n<li>To determine the median number of delivered courses of this regimen in these patients.</li>\n<li>To determine the overall response rate (i.e., complete and partial response) in patients treated with this regimen.</li>\n<li>To determine the progression-free survival of patients treated with this regimen.</li>\n<li>To correlate response with baseline biologic factors (IgVH, FISH, ZAP-70, CD38).</li>\n</ul>\n OUTLINE: This is a multicenter, phase I, dose-escalation study of lenalidomide followed by a phase II study. Patients receive oral lenalidomide on days 1-14 and fludarabine IV over 30 minutes and cyclophosphamide IV over 15-20 minutes on days 1-3. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for up to 5 years.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:b547e4a4a64449564310e07702ad85e1' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:9429e40cab9c94faab64f7da5a4f96a3' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'DISEASE CHARACTERISTICS:\n<ul>\n<li>Diagnosis of chronic lymphocytic leukemia meeting the following criteria:\n<ul>\n<li>Advanced or progressive disease</li>\n<li>Relapsed or refractory disease</li>\n</ul>\n</li>\n</ul>\n PATIENT CHARACTERISTICS:\n<ul>\n<li>ECOG performance status 0-2</li>\n<li>Serum creatinine ≤ 1.5 mg/dL</li>\n<li>Creatinine clearance > 50 mL/min</li>\n<li>Total bilirubin ≤ 1.5 mg/dL</li>\n<li>AST and ALT ≤ 1.5 times upper limit of normal</li>\n<li>Able to take low molecular weight heparin</li>\n<li>Able to adhere to the study visit schedule and other study requirements</li>\n<li>Not pregnant or nursing\n<ul>\n<li>No nursing during and for ≥ 28 days after completion of study treatment</li>\n</ul>\n</li>\n<li>Negative pregnancy test</li>\n<li>Fertile patients must use effective double-method contraception for ≥ 28 days prior to, during, and for ≥ 6 months after completion of study treatment</li>\n<li>No blood, semen, or sperm donation during and for ≥ 28 days after completion of study treatment</li>\n<li>No other malignancies within the past 5 years, except treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast</li>\n<li>No positive direct antiglobulin test (DAT) with clinical and laboratory signs of hemolysis or autoimmune thrombocytopenia</li>\n<li>No known positivity for HIV or active infectious hepatitis</li>\n<li>No active bacterial, viral, or fungal infection requiring systemic anti-viral, antibiotic, or antifungal therapy</li>\n<li>No prior or concurrent thrombosis, thromboembolism, heart failure, arrhythmia, neurologic disease, or renal insufficiency</li>\n<li>No serious medical condition, laboratory abnormality, or psychiatric illness that would preclude giving informed consent</li>\n<li>No condition, including the presence of laboratory abnormalities, that would place the patient at unacceptable risk or confound the ability to interpret study data</li>\n<li>No known hypersensitivity to thalidomide</li>\n<li>No development of erythema nodosum or desquamating rash while taking thalidomide or similar drugs</li>\n</ul>\n PRIOR CONCURRENT THERAPY:\n<ul>\n<li>No prior lenalidomide</li>\n<li>No more than 2 prior treatment regimens</li>\n<li>More than 6 months since prior alemtuzumab</li>\n<li>At least 4 weeks since prior cancer therapy (e.g., chemotherapy, immunotherapy, or surgery)</li>\n<li>More than 28 days since prior experimental drug or therapy</li>\n<li>No other concurrent anticancer agents or treatments (e.g., thalidomide or radiotherapy)</li>\n<li>No other concurrent investigational agents</li>\n<li>No concurrent sargramostim (GM-CSF)</li>\n<li>No concurrent erythropoietin</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:9429e40cab9c94faab64f7da5a4f96a3' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:0e79568ecdbbf006d075c1c708fed460' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Progression-free survival [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:0e79568ecdbbf006d075c1c708fed460' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:0c662c9aa299a69083abe115daccf333' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Overall response rate [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:0c662c9aa299a69083abe115daccf333' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:71cfadbf296c0ebe22fada5ed24e0760' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Toxicity as assessed by NCI CTCAE v3.0 [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:71cfadbf296c0ebe22fada5ed24e0760' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:3b00931d899bcbe80566d5f245b6993e' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Maximum tolerated dose of lenalidomide (Phase I) [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:3b00931d899bcbe80566d5f245b6993e' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:67d3182c847a7c0060bc5d6ecb4e2181' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Overall complete response (CR) rate (Phase II) [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:67d3182c847a7c0060bc5d6ecb4e2181' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:e35302769d9c7885723fa6da7192aef9' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'CR rate (Phase I) [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:e35302769d9c7885723fa6da7192aef9' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:8a3b1c4d44800bcdfe137d3ba30a5f79' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Infection rate [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:8a3b1c4d44800bcdfe137d3ba30a5f79' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:68fb7a8b732b22170e14a8e2346ec3b2' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Median number of delivered courses of treatment [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:68fb7a8b732b22170e14a8e2346ec3b2' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:c34f5024bfba82bb7846550d4fbd0241' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Correlation between response and baseline biologic parameters (i.e., IgVH, FISH, ZAP-70, CD38) [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:c34f5024bfba82bb7846550d4fbd0241' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:83093853389028cd1080b0720e1d5b9d' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:83093853389028cd1080b0720e1d5b9d' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:e682a05167afedd5b7847872f75934f5' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'A Randomized Comparison of Oral Methadone as a "First-Switch" Opioid Versus Opioid Switching Between Sustained-Release Morphine and Oxycodone for Oncology-Hematology Outpatients With Pain Management Problems: The "Simply Rotate" Study\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:e682a05167afedd5b7847872f75934f5' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:76802cc08dc38182f705aec18b74013c' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'OBJECTIVES: Primary\n<ul>\n<li>To compare the effectiveness of an opioid rotation to oral methadone versus an opioid rotation to another long-acting strong opioid (sustained-release morphine or oxycodone) in controlling pain (i.e., analgesia) in patients with cancer.</li>\n</ul>\n Secondary\n<ul>\n<li>To compare the tolerability of an opioid rotation to oral methadone versus an opioid rotation to another long-acting strong opioid (sustained-release morphine or oxycodone).</li>\n<li>To identify a subset of patients most likely to benefit from an opioid rotation to oral methadone, in terms of significant improvement in pain control or opioid tolerability.</li>\n</ul>\n OUTLINE: This is a multicenter study. Patients are stratified according to their baseline opioid (morphine vs oxycodone). Patients are randomized to 1 of 2 treatment arms.\n<ul>\n<li>Arm I: Patients are switched from their current opioid medication (oxycodone or morphine) to methadone. Patients receive oral methadone 2-3 times daily for 4 weeks.</li>\n<li>Arm II: Patients currently receiving oxycodone are switched to sustained-release (SR) morphine. Patients currently receiving morphine are switched to SR oxycodone. Patients receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.</li>\n</ul>\n Patients are assessed for pain control and complete a symptom questionnaire on days 1, 8, 15, 22, and 28.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:76802cc08dc38182f705aec18b74013c' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:b46412cca3c03de4baffb656fd8990bb' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'DISEASE CHARACTERISTICS:\n<ul>\n<li>Receiving ongoing care in the outpatient medical oncology setting</li>\n<li>Self-reported pain (of any cause) for which long-acting strong opioids (morphine or oxycodone) have been prescribed or administered\n<ul>\n<li>Oral morphine-equivalent daily dose (MEDD) of existing opioid regimen (long-acting or immediate-release) 40-300 mg/day</li>\n</ul>\n</li>\n<li>Worst pain score on a scale of 0 (no pain) to 10 (worst pain) of ≥ 5 for ≥ 1 week duration based on verbal self-report AND/OR ≥ 1 persistently bothersome symptom attributed to an opioid side effect (e.g., fatigue, confusion, depressed level of consciousness, memory loss, personality change, anorexia, constipation, dehydration, nausea, vomiting, weight loss, pruritus, urticaria, impotence, reduced libido, and urinary retention or hesitancy)</li>\n</ul>\n PATIENT CHARACTERISTICS:\n<ul>\n<li>None of the following conditions that could predispose the patient to prolonged QT interval-associated tachycardia:\n<ul>\n<li>Serum potassium < 3.0 mg/dL</li>\n<li>Cocaine abuse within the past 3 months</li>\n<li>Family history of sudden death</li>\n<li>Advanced heart failure (ejection fraction < 40% and/or NYHA class III or IV heart disease)</li>\n</ul>\n</li>\n<li>No known or suspected cognitive impairment that could interfere with adherence to the medication plan or self-report of symptoms and side effects</li>\n<li>Not pregnant or nursing</li>\n<li>Fertile patients must use effective contraception</li>\n</ul>\n PRIOR CONCURRENT THERAPY:\n<ul>\n<li>See Disease Characteristics</li>\n<li>More than 4 weeks since prior radiotherapy or surgery for local control of cancer or pain palliation</li>\n<li>More than 60 days since prior use of the same long-acting opioid (i.e., the new long-acting opioid) that patient is switching to on the study</li>\n<li>More than 12 weeks since prior methadone therapy</li>\n<li>More than 3 days since prior and no concurrent transdermal fentanyl, oxymorphone, or buprenorphine</li>\n<li>Concurrent systemic anticancer therapy or bisphosphonates allowed provided therapy was initiated ≥ 4 weeks ago</li>\n<li>Concurrent tricyclic antidepressants, NSAIDs, anticonvulsants, or other adjuvant analgesics or psychostimulants allowed provided therapy was initiated ≥ 2 weeks ago\n<ul>\n<li>Dose expected to remain stable until after the first week of opioid rotation on study</li>\n</ul>\n</li>\n<li>No concurrent methadone maintenance therapy for opioid addiction</li>\n<li>No concurrent intrathecal infusion of analgesics</li>\n<li>No concurrent antiarrhythmic medications (e.g., amiodarone or quinidine)</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:b46412cca3c03de4baffb656fd8990bb' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:16e9ff6530662c4e767ab2cbf540d2e9' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '30% reduction in patients\' total summary score for the individual composite drug toxicity score (CDTS) items [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:16e9ff6530662c4e767ab2cbf540d2e9' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a745fbf8b3911431b7c93870d4965fdf' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Identification of a subset of patients most likely to benefit from an opioid rotation to oral methadone, in terms of significant improvement in pain control or opioid tolerability [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a745fbf8b3911431b7c93870d4965fdf' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:352d70193ede05ded78f86e5a49c20d4' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: A donor peripheral stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient\'s bone marrow make stem cells, red blood cells, white blood cells, and platelets. Once the donated stem cells begin working, the patient\'s immune system may see the remaining cancer cells as not belonging in the patient\'s body and destroy them. Giving an infusion of donor T cells may helps stop the patient\'s immune system from rejecting the donor\'s stem cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of donor T cells in treating patients with high-risk hematologic cancer who are undergoing donor peripheral blood stem cell transplant.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:352d70193ede05ded78f86e5a49c20d4' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:e5186cd5855132b57983e764d3b6af1b' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'MT2004-03: A Clinical Trial of Adult CD4+ CD25+ Regulatory T Cells in BMT Recipients Was "A Dose Escalation Study of CD4+ CD25+ Cells in Adult Patients Undergoing HLA-Identical Sibling Donor Peripheral Blood Progenitor Cell (PBPC) Transplantation&quo\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:e5186cd5855132b57983e764d3b6af1b' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:88cc5b5198290b5cc0e09b556cb0785e' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'OBJECTIVES: Primary\n<ul>\n<li>To determine whether CD4- and CD25-positive regulatory T cells can be safely administered to patients with high-risk hematologic malignancies undergoing HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation.</li>\n</ul>\n Secondary\n<ul>\n<li>To determine the incidence of grade II-IV acute graft-versus-host-disease (GVHD), chronic GVHD, relapse, and survival after administration of CD4- and CD25-positive regulatory T cells in these patients.</li>\n</ul>\n OUTLINE: This is a dose-escalation study of CD4- and CD25-positive donor regulatory T cells followed by a phase II study. All patients receive myeloablative preparative therapy and GVHD prophylaxis as per University of Minnesota protocol UMN-MT2001-02 or UMN-MT2001-10.\n<ul>\n<li>First allogeneic peripheral blood progenitor cell (PBPC) infusion: Patients receive unmobilized, culture-expanded, CD4- and CD25-positive donor regulatory T cells IV over 15-60 minutes at the assigned dose on day -2.</li>\n<li>Second allogeneic PBPC infusion: Patients undergo matched-sibling donor PBPC transplantation IV on day 0.</li>\n</ul>\n Patients undergo blood sample collection prior to commencement of preparative therapy and then at day 100, 6 months, and 1 year after PBPC transplantation. Samples are analyzed for immune reconstitution by immunophenotyping and functional analyses. After completion of study therapy, patients are followed for up to 1 year.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:88cc5b5198290b5cc0e09b556cb0785e' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:cf0204f2091e71d9a29007de741d118d' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'DISEASE CHARACTERISTICS:\n<ul>\n<li>Diagnosis of a high-risk hematologic malignancy, including any of the following:\n<ul>\n<li>Acute lymphoblastic leukemia (ALL) beyond second complete remission (CR2)</li>\n<li>Acute myeloid leukemia beyond CR2</li>\n<li>Chronic myelogenous leukemia in accelerated phase or post-blast crisis</li>\n<li>Myelodysplastic syndromes with 5-20% blasts in bone marrow</li>\n<li>Non-Hodgkin lymphoma beyond third partial remission</li>\n<li>Multiple myeloma meeting the following criterion:\n<ul>\n<li>Not a candidate for autologous stem cell transplantation</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Must have an HLA-identical sibling donor available, meeting the following criteria:\n<ul>\n<li>12 to 75 years of age</li>\n<li>Matched to recipient for HLA-A and -B antigens using serological techniques and for DRB1 allele level using SSOP typing UMN-MT2001-02</li>\n</ul>\n</li>\n<li>Concurrently enrolled on 1 of the following protocols:\n<ul>\n<li>UMN-MT2001-02</li>\n<li>UMN-MT2001-10</li>\n</ul>\n</li>\n</ul>\n PATIENT CHARACTERISTICS:\n<ul>\n<li>Not specified</li>\n</ul>\n PRIOR CONCURRENT THERAPY:\n<ul>\n<li>See Disease Characteristics</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:cf0204f2091e71d9a29007de741d118d' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:955254cde948984eb9e60ebac1471e8a' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Disease-free survival [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:955254cde948984eb9e60ebac1471e8a' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:1e8c637579fde6f0fcb8a2651fdb18a9' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Maximum tolerated dose (Phase I) [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:1e8c637579fde6f0fcb8a2651fdb18a9' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:304374ea3ca2a087b59d8e9d97059a92' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of grade 3-5 infusional toxicity at 48 hours after a CD4- and CD25-positive regulatory T-cell infusion (phase II) [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:304374ea3ca2a087b59d8e9d97059a92' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:c23c82efd2f0577ba704d51488708c2e' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Cumulative incidence of grade II-IV acute graft-versus-host-disease (GVHD) at day 100 [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:c23c82efd2f0577ba704d51488708c2e' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:4e3050674aeef45c053bbe3dc185e71a' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of chronic GVHD at 6 months [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:4e3050674aeef45c053bbe3dc185e71a' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:3742cbea75676c7d2a67a4ff75040626' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Relapse at 6 months [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:3742cbea75676c7d2a67a4ff75040626' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:eec69a9d1c23f750a0cbcc0bd1a4d41f' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Survival at 100 days and 1 year [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:eec69a9d1c23f750a0cbcc0bd1a4d41f' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:4606142909cf59467d26a02be1c1df23' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant related mortality.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:4606142909cf59467d26a02be1c1df23' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:1dc2e8c115a755f0862667c8d7395077' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Clofarabine Bone Marrow Cytoreduction : Feasibility of Induction as a Bridge to Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Acute Leukemias, Myelodysplastic Syndromes, and Advanced Myeloproliferative Diseases.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:1dc2e8c115a755f0862667c8d7395077' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:aa14c564a87448cc2aaaf406502cb0d6' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Screening will be done prior to enrollment in the study. The following will be done as part of the screening process:\n<ul>\n<li>Medical history review</li>\n<li>Physical exam</li>\n<li>Measurement of vital Signs</li>\n<li>Blood tests (approximately 6 teaspoons of blood) will be done to see if the liver and kidneys are healthy, HIV (the virus that causes AIDS) test for this study and pregnancy test.</li>\n<li>Urine test</li>\n<li>Bone marrow biopsy and aspirate</li>\n</ul>\n If the patient is ineligible or does not have a donor for Allogeneic Stem Cell transplantation, you will not be able to participate in this clinical trial. After results of these tests are obtained, your doctor will decide whether you can participate in this study. Study procedures: The study drug will be given for 5 days. Days 1 through 5: The patient will receive dexamethasone 1.5 hours prior to the administration of Clofarabine as part of standard care for subjects receiving Clofarabine. Teh patient will receive an intravenous (IV) injection (into the vein) of Clofarabine each day for 5 days. This injection is given in the hospital and will be given over approximately 60 minutes each day. The actual dose of Clofarabine is based on the weight and height of the subject. The patient will have the following tests done to see the effects of the study drug: Each day of Clofarabine administration, on day 12 and then each day until stem cell transplantation:\n<ul>\n<li>Physical exam</li>\n<li>Vital signs</li>\n<li>Blood tests. About 3-4 teaspoons will be taken each time.</li>\n</ul>\n Day 12 after Clofarabine administration and then as outlined for stem cell transplantation:\n<ul>\n<li>Bone marrow biopsy and aspirate.</li>\n</ul>\n After Clofarabine administration, there will be short resting period of 7-14 days. After the resting period, the patient will start receiving conditioning chemotherapy regimen (other standard of care drugs to better prepare your body for the stem cell transplant). This regimen will begin 15-21 days after they first received Clofarabine, and consists of additional treatment (chemotherapy and/or radiation). The type of treatment(s) the patient will receive for conditioning is dependent on the type of disease. In addition, this treatment will be decided by your doctor and is independent of this research. The duration of the conditioning period is variable and may take between 5-8 days. Stem cells are usually given one day after the completion of this regimen, which will be between 21 and 30 days after the patient has first received Clofarabine. Follow-up Subjects who have a response and proceed with stem cell transplant will be followed weekly for the first three months and then every month for six months, then every two months for 12 months, then every three months for 18 months. The stem cell transplant will be done 21-30 days after first receiving Clofarabine. Subjects who do not go on to stem cell transplant will be followed for 3 months following administration of Clofarabine. At these visits, the following will be done:\n<ul>\n<li>A physical exam</li>\n<li>Medical history</li>\n<li>Blood tests (about 3 teaspoons blood will be taken) performed.</li>\n</ul>\n End of study At this time, the following tests will be done:\n<ul>\n<li>Physical exam</li>\n<li>Blood tests</li>\n<li>Bone marrow biopsy</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:aa14c564a87448cc2aaaf406502cb0d6' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:1e592cb8cd0e94532b7b76bd415c0ef3' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Inclusion Criteria:\n<ul>\n<li>Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.</li>\n<li>Adequate hepatobiliary function as indicated by the following laboratory values:\n<ul>\n<li>SGOT/SGPT <=2.5 x upper limit of normal</li>\n<li>Alkaline phosphatase <=2.5 x upper limit of normal</li>\n<li>Serum bilirubin < 1.5 mg/dl</li>\n<li>Adequate renal function as indicated by the following laboratory values:</li>\n<li>Creatinine Clearance >50 ml/min</li>\n</ul>\n</li>\n<li>Age >/=18 years</li>\n<li>Zebroid performance status </= 2 (See Appendix A)</li>\n<li>Life expectancy is not severely limited by concomitant illness (i.e. < 3months life expectancy from non-leukemic conditions).</li>\n<li>No evidence of chronic active hepatitis or cirrhosis.</li>\n<li>HIV-negative</li>\n<li>Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.</li>\n<li>Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.</li>\n</ul>\n Exclusion Criteria:\n<ul>\n<li>Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.</li>\n<li>Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute non-hematologic toxicities from any previous .</li>\n<li>Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.</li>\n<li>Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).</li>\n<li>Pregnant or lactating patients.</li>\n<li>Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:1e592cb8cd0e94532b7b76bd415c0ef3' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:16b1b175e81c8c58a60d4cbd64a85fb4' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in treating patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:16b1b175e81c8c58a60d4cbd64a85fb4' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:d56ae30d293602a43534d8b93642fbcc' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:d56ae30d293602a43534d8b93642fbcc' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:5d5ede86538b12664a13b34c0916b24c' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'OBJECTIVES: Primary\n<ul>\n<li>To determine the antitumor activity of panobinostat, in terms of objective response rate, time to progression, and survival, in patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.</li>\n<li>To assess the toxicity of panobinostat in these patients.</li>\n</ul>\n Secondary\n<ul>\n<li>To perform correlative laboratory studies to assess changes in various proteins that may be altered by histone deacetylase inhibition therapy.</li>\n</ul>\n OUTLINE: Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients undergo peripheral blood and bone marrow sample collection at baseline and on day 28 of course 1 for correlative laboratory studies. Samples are analyzed by RT-PCR for reactivation of FANCG, FOXO3A, GADD45A, GADD45B, GADD45G, H2AX, and TP73. After completion of study treatment, patients are followed for at least 4 weeks. PROJECTED ACCRUAL: A total of 74 patients (37 with acute myeloid leukemia and 37 with acute lymphoblastic leukemia) will be accrued for this study.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:5d5ede86538b12664a13b34c0916b24c' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:c5bb4c9ea54690b326cca8b53f2dfc50' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'DISEASE CHARACTERISTICS:\n<ul>\n<li>Histologically or cytologically confirmed acute myeloid leukemia or acute lymphoblastic leukemia (ALL)\n<ul>\n<li>Relapsed or refractory disease</li>\n</ul>\n</li>\n<li>Patients with Philadelphia chromosome-positive (Ph+) ALL refractory to BCR/ABL inhibitors are eligible</li>\n<li>Patients who have relapsed after prior autologous or allogenic stem cell transplant are eligible</li>\n<li>No active CNS disease</li>\n</ul>\n PATIENT CHARACTERISTICS:\n<ul>\n<li>ECOG performance status 0-2</li>\n<li>Serum albumin ≥ 3 g/dL</li>\n<li>AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN if transaminase elevation is due to leukemic involvement)</li>\n<li>Bilirubin ≤ 1.5 times ULN</li>\n<li>Creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 mL/min</li>\n<li>Potassium ≥ lower limit of normal (LLN)</li>\n<li>Phosphorous ≥ LLN</li>\n<li>Serum total calcium (corrected for serum albumin) or serum ionized calcium ≥ LLN</li>\n<li>Magnesium ≥ LLN</li>\n<li>Thyroid stimulating hormone and free T4 normal (thyroid hormone replacement therapy allowed)</li>\n<li>LVEF ≥ LLN by MUGA or ECHO</li>\n<li>No impaired cardiac function, including any of the following:\n<ul>\n<li>QTc > 450 msec</li>\n<li>Congenital long QT syndrome</li>\n<li>History of sustained ventricular tachycardia</li>\n<li>History of ventricular fibrillation or torsades de pointes</li>\n<li>Bradycardia (i.e., heart rate < 50 beats per minute)\n<ul>\n<li>Pacemaker allowed provided heart rate ≥ 50 beats per minute</li>\n</ul>\n</li>\n<li>Myocardial infarction or unstable angina within the past 6 months</li>\n<li>New York Heart Association class III-IV congestive heart failure</li>\n<li>Right bundle branch block and left anterior hemiblock (bifascicular block)</li>\n</ul>\n</li>\n<li>No uncontrolled hypertension</li>\n<li>No unresolved diarrhea > CTCAE grade 1</li>\n<li>No impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat</li>\n<li>Not pregnant or nursing</li>\n<li>Negative pregnancy test</li>\n<li>Fertile patients must use effective double-barrier contraception during and for 3 months after completion of study treatment</li>\n<li>No other primary malignancy within the past 5 years, other than curatively treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin</li>\n<li>No HIV or hepatitis C positivity</li>\n<li>No other concurrent severe and/or uncontrolled medical condition</li>\n<li>No significant history of non-compliance to medical regimens or inability to give reliable informed consent</li>\n</ul>\n PRIOR CONCURRENT THERAPY:\n<ul>\n<li>See Disease Characteristics</li>\n<li>Recovered from all prior therapy</li>\n<li>More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy</li>\n<li>More than 4 weeks since prior valproic acid</li>\n<li>No other prior treatment with a histone deacetylase inhibitor</li>\n<li>No concurrent medication that may cause QTc prolongation or induce torsades de pointes</li>\n<li>No concurrent CYP3A4 inhibitors</li>\n<li>No concurrent grapefruit, grapefruit juice, or Seville (sour) oranges</li>\n<li>No concurrent radiotherapy</li>\n<li>No other concurrent anticancer therapy or investigational therapy</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:c5bb4c9ea54690b326cca8b53f2dfc50' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:e760e13ccf51ba2a55bfe1ce9261f68a' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Toxicity [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:e760e13ccf51ba2a55bfe1ce9261f68a' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a9cf1b60cee59581ac836c2a5fd32de1' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Overall survival [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a9cf1b60cee59581ac836c2a5fd32de1' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:64c94527c722c897a14033e356f8eb6b' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Time to progression [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:64c94527c722c897a14033e356f8eb6b' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:b90917257a6ce368b4a6072698f4bc01' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Assessment of biological correlates [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:b90917257a6ce368b4a6072698f4bc01' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:e00d60aede74a721deb8c3df27a225b7' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells and helps stop the patient\'s immune system from rejecting the donor\'s stem cells. When the stem cells from an unrelated donor, that do not exactly match the patient\'s blood, are infused into the patient they may help the patient\'s bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body\'s normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well umbilical cord blood transplant from an unrelated donor works in treating patients with hematologic cancer.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:e00d60aede74a721deb8c3df27a225b7' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:c01c6e81a950af7e06fbfb739324789c' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:c01c6e81a950af7e06fbfb739324789c' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:ae05d7e8ce3c634a8c0c7443d5d2ed6e' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'OBJECTIVES: Primary\n<ul>\n<li>To estimate probability of 1-year survival of patients with hematological malignancies undergoing a reduced-intensity preparative regimen during unrelated donor umbilical cord blood transplantation.</li>\n<li>To demonstrate equivalent or improved engraftment rates with a nonanti-thymocyte-based conditioning regimen in patients who have not received recent chemotherapy (stratum 2).</li>\n</ul>\n Second\n<ul>\n<li>To determine the 6-month nonrelapse mortality in patients treated with this regimen.</li>\n<li>To determine the overall incidence of graft failure/rejection in patients treated with this regimen.</li>\n<li>To determine the kinetics of chimeric reconstitution in patients treated with this regimen.</li>\n<li>To determine the incidence of neutrophil engraftment by day 42 in patients treated with this regimen.</li>\n<li>To determine the incidence of platelet engraftment by 6 months in patients treated with this regimen.</li>\n<li>To determine the incidence of grade II-IV and III-IV acute graft-versus-host-disease (GVHD) for each stratum in patients treated with this regimen.</li>\n<li>Incidence of one-year chronic GVHD for each stratum in patients treated with this regimen.</li>\n<li>Incidence of clinically significant infections at 6 months, 1 year, and 2 years for each stratum in patients treated with this regimen.</li>\n<li>To determine the probability of 1- and 2-year survival of patients treated with this regimen.</li>\n<li>To determine the incidence of 1- and 2-year relapse or disease progression in patients treated with this regimen.</li>\n</ul>\n OUTLINE: This is a multicenter study. Patients are stratified according to risk of graft rejection (low vs high).\n<ul>\n<li>Reduced-intensity preparative regimen with graft-vs-host disease prophylaxis: Patients receive fludarabine phosphate IV on day -6 through day -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo total-body irradiation on day -1.</li>\n<li>Donor umbilical cord blood infusion: Patients undergo donor umbilical cord blood infusion on day 0.</li>\n<li>Graft-vs-host disease prophylaxis: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to +180 and mycophenolate mofetil IV or orally every 8 hours on days -3 to +96. Patients are followed periodically for up to 2 years after transplantation.</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:ae05d7e8ce3c634a8c0c7443d5d2ed6e' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:88be77144a1a939105c8055212142f73' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'DISEASE CHARACTERISTICS:\n<ul>\n<li>Diagnosis of any of the following diseases (other diagnoses may be considered)\n<ul>\n<li>Acute myeloid leukemia with < 5% morphologic marrow blasts in an evaluable marrow (> 25% of normal cellularity for age)</li>\n<li>Acute lymphoblastic leukemia with < 5% morphologic marrow blasts in an evaluable marrow (> 25% of normal cellularity for age)</li>\n<li>Chronic myelogenous leukemia (CML) with < 5% blasts in an evaluable marrow (> 25% of normal cellularity for age) by morphology\n<ul>\n<li>All types allowed except refractory blast crisis</li>\n<li>Patients with chronic phase CML must be refractory or intolerant to imatinib mesylate or other tyrosine kinase inhibitors</li>\n</ul>\n</li>\n<li>Myelodysplastic syndromes (MDS) with morphologic blasts less than 5% in an evaluable marrow (> 25% of normal cellularity for age)\n<ul>\n<li>If blasts are 5% or more, patient must undergo induction therapy pretransplant to reduce blast count to ≤ 5%</li>\n<li>Any subtype allowed</li>\n</ul>\n</li>\n<li>Large-cell lymphoma or aggressive T-cell lymphoma, meeting 1 of the following criteria:\n<ul>\n<li>Chemotherapy-sensitive disease (defined as ≥ 50% reduction in the size of the tumor with the chemotherapy regimen immediately preceding transplant) that has failed autologous transplantation</li>\n<li>Ineligible for an autologous transplant</li>\n</ul>\n</li>\n<li>Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), meeting 1 of the following criteria:\n<ul>\n<li>Refractory to fludarabine or did not achieve a complete or partial response after therapy with a regimen containing fludarabine or another nucleoside analog (e.g., 2-CDA or pentostatin)</li>\n<li>Disease relapse within 12 months after completing therapy with a regimen containing fludarabine or another nucleoside analog</li>\n</ul>\n</li>\n<li>Hodgkin lymphoma\n<ul>\n<li>Refractory to prior front-line therapy</li>\n</ul>\n</li>\n<li>Follicular lymphoma, marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, or indolent T-cell lymphomas\n<ul>\n<li>Disease progressed; most recent remission duration < 6 months</li>\n<li>Patients with bulky disease should be considered for debulking chemotherapy before transplant</li>\n<li>Patients with refractory disease are eligible, unless they have bulky disease and an estimated tumor doubling time of less than one month</li>\n</ul>\n</li>\n<li>Multiple myeloma\n<ul>\n<li>Must have received prior chemotherapy; prior consolidation of chemotherapy by autografting prior to nonmyeloablative hematopoietic stem cell transplantation allowed</li>\n</ul>\n</li>\n<li>Myeloproliferative syndromes</li>\n</ul>\n</li>\n<li>Meets 1 of the following criteria for risk of graft rejection\n<ul>\n<li>At lower risk for graft failure, meeting 1 of the following criteria (stratum 1):\n<ul>\n<li>Received a previous autologous transplant within the past 12 months</li>\n<li>Received ≥ 2 courses of multiagent chemotherapy with ≥ 1 course of therapy within the past 3 months\n<ul>\n<li>Chemotherapy is defined as cytotoxic therapy with the intention of inducing complete response; targeted therapeutics including, but not limited to, histone deacetylase inhibitors, hypomethylating agents, immunomodulatory agents, and tyrosine kinase inhibitors are not considered chemotherapies</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>At higher risk for graft failure (stratum 2)\n<ul>\n<li>Have not undergone autologous transplantation within the past 12 months, and meets 1 of the following criteria:\n<ul>\n<li>Received < 2 courses of multiagent chemotherapy</li>\n<li>Received no multiagent chemotherapy within the past 3 months</li>\n</ul>\n</li>\n<li>Patients who have experienced graft failure following prior allogeneic transplantation are allowed</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Patient and the cord blood unit(s) must be matched for at least 4 of 6 loci\n<ul>\n<li>No 5-6/6 HLA-A, -B, -DRB1 matched-sibling donor or 10/10 matched-unrelated donor available</li>\n</ul>\n</li>\n<li>No active central nervous system malignancy</li>\n</ul>\n PATIENT CHARACTERISTICS:\n<ul>\n<li>Karnofsky performance status (PS) 60-100% (for adults) or Lansky PS 50-100% (for children)</li>\n<li>No decompensated congestive heart failure or uncontrolled arrhythmia</li>\n<li>LVEF ≥ 35%</li>\n<li>DLCO > 30% predicted</li>\n<li>No requirement for supplemental oxygen</li>\n<li>Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, histology, and the degree of portal hypertension; patients with the following hepatic conditions will be ineligible:\n<ul>\n<li>Fulminant liver failure</li>\n<li>Cirrhosis with evidence of portal hypertension or bridging fibrosis</li>\n<li>Alcoholic hepatitis</li>\n<li>Esophageal varices</li>\n<li>History of bleeding esophageal varices</li>\n<li>Hepatic encephalopathy</li>\n<li>Correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time</li>\n<li>Ascites related to portal hypertension</li>\n<li>Bacterial or fungal abscess</li>\n<li>Biliary obstruction</li>\n<li>Chronic viral hepatitis with total serum bilirubin > 3 mg/dL</li>\n<li>Symptomatic biliary disease</li>\n</ul>\n</li>\n<li>Creatinine < 2.0 mg/dL (adults)\n<ul>\n<li>Adults with creatinine > 1.2 mg/dL or history of renal dysfunction must have estimated creatinine clearance > 40 mL/min</li>\n</ul>\n</li>\n<li>Creatinine clearance > 40 mL/min (pediatrics)</li>\n<li>Not pregnant or nursing</li>\n<li>Fertile patients must use effective contraception</li>\n<li>No evidence of HIV infection or known HIV-positive serology</li>\n<li>No uncontrolled viral or bacterial infection\n<ul>\n<li>Recent mold infection (e.g., Aspergillus) allowed provided the patient has received a minimum of 30 days of appropriate treatment; infection must be controlled</li>\n<li>No active or recent (within the previous 6 months) invasive fungal infection without Infectious Disease consult and approval</li>\n</ul>\n</li>\n</ul>\n PRIOR CONCURRENT THERAPY:\n<ul>\n<li>See Disease Characteristics</li>\n<li>At least 3 months since prior myeloablative transplantation</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:88be77144a1a939105c8055212142f73' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:0e79568ecdbbf006d075c1c708fed460' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Progression-free survival [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:0e79568ecdbbf006d075c1c708fed460' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:396cbeb3ce660f8b5c8bea6303bc0b67' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Relapse [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:396cbeb3ce660f8b5c8bea6303bc0b67' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a07c05731de9857f46ad56bd19af5ccf' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Survival at 1 year [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a07c05731de9857f46ad56bd19af5ccf' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a2a232380332aea5e4fc33a57ab6b75c' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Acute and chronic GVHD [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a2a232380332aea5e4fc33a57ab6b75c' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:dae817d15fd0a31be0a830f07ce73f9c' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Engraftment rates [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:dae817d15fd0a31be0a830f07ce73f9c' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:0ef948118a739a7e0a702e8bcc38665d' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Overall survival (i.e., beyond 1 year) [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:0ef948118a739a7e0a702e8bcc38665d' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:23aa2a1679892cefc0edaebf80a67752' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Nonrelapse mortality at 6 months, 1 year, and overall [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:23aa2a1679892cefc0edaebf80a67752' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:20f30ddcd038268ca6b0197aafbad2d6' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of graft failure/rejection [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:20f30ddcd038268ca6b0197aafbad2d6' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:d62a5110a9f53861e9a571b1f072f620' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Neutrophil and platelet engraftment [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:d62a5110a9f53861e9a571b1f072f620' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:901b0c4238873f5dbf9931efb1e1b857' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Clinically significant infections [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:901b0c4238873f5dbf9931efb1e1b857' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:800f2625afc9a14e5707ee32e0855126' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:800f2625afc9a14e5707ee32e0855126' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:71cfadbf296c0ebe22fada5ed24e0760' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Toxicity as assessed by NCI CTCAE v3.0 [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:71cfadbf296c0ebe22fada5ed24e0760' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:20ba70b486a7f54330c3e5d10f9bb9ab' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '3-year event-free survival (EFS) of patients with standard-risk disease treated with dasatinib in combination with intensified chemotherapy [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:20ba70b486a7f54330c3e5d10f9bb9ab' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:8bc5c2f78c4f88b5ea3d162786e6e866' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Overall 3-year EFS rate for both standard- and high-risk patients [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:8bc5c2f78c4f88b5ea3d162786e6e866' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:dc4a3bfa3c0c641f863998196f3c1f6e' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient\'s immune system from rejecting the donor\'s stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient\'s blood, are infused into the patient they may help the patient\'s bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body\'s normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well umbilical cord blood transplant given together with cyclophosphamide, fludarabine, and total-body irradiation works in treating patients with hematologic disease.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:dc4a3bfa3c0c641f863998196f3c1f6e' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:8e3bec6ea723cdc059b530d2035cb8ee' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:8e3bec6ea723cdc059b530d2035cb8ee' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:4f85805d5a35396ee5e0f643a8d3b4e4' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'OBJECTIVES: Primary\n<ul>\n<li>The 1-year survival of patients with hematological malignancies undergoing umbilical cord blood transplantation after a myeloablative preparative regimen comprising of cyclophosphamide, fludarabine, and fractionated total-body irradiation.</li>\n</ul>\n Secondary\n<ul>\n<li>The incidence of transplant-related mortality at 6 months.</li>\n<li>The chimerism at multiple time points.</li>\n<li>The incidence of neutrophil engraftment at day 42.</li>\n<li>The incidence of platelet engraftment at 6 months.</li>\n<li>The incidence of acute graft-versus-host disease (GVHD) grade II-IV and grade III-IV at day 100.</li>\n<li>The incidence of chronic GVHD at day 100, 1 year, and 2 years.</li>\n<li>The incidence of clinically significant infections at 6 months, 1 year, and 2 years.</li>\n<li>The incidence of disease-free survival at 1 and 2 years.</li>\n<li>The incidence of relapse at 1 and 2 years.</li>\n</ul>\n OUTLINE:\n<ul>\n<li>Conditioning regimen: Patients receive fludarabine IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo total-body irradiation twice daily on days -4 to -1.</li>\n<li>Umbilical cord blood transplantation (UCBT): Patients undergo UCBT on day 0. Patients receive filgrastim (G-CSF) IV (pediatric) or subcutaneously (adult) beginning on day 1 and continuing until blood counts recover.</li>\n<li>Graft-versus-host disease prophylaxis (GVHD): Patients receive cyclosporine orally or IV over 1 hour twice daily (adult) or three times daily (pediatric) beginning on day -3 and continuing until day 100 and then taper. Patients also receive mycophenolate mofetil (MMF) IV three times daily on days -3 to 5 and then orally on days 6-30. MMF will be discontinued on day 30 or 7 if there is no acute GVHD.</li>\n</ul>\n After completion of study treatment, patients are followed at 6 months, 1 year, and 2 years.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:4f85805d5a35396ee5e0f643a8d3b4e4' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:79283ad5727bf84551b4f8e69168df2c' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'DISEASE CHARACTERISTICS:\n<ul>\n<li>Diagnosis of hematological malignancy, meeting any of the following criteria:\n<ul>\n<li>Acute Myeloid Leukemia (AML)\n<ul>\n<li>High-risk complete remission (CR) 1 as evidenced by preceding myelodysplastic syndrome (MDS), high risk cytogenetics (e.g., monosomy 5 or 7) OR high-risk as defined by referring institution treatment protocol, ≥ 2 courses to obtain CR, erythroblastic or megakaryocytic leukemia, and ≥ CR2</li>\n<li>All patients must be in CR as defined by hematologic recovery and < 5% blasts by morphology within the bone marrow and a cellularity of\n<ul>\n<li>15%</li>\n</ul>\n</li>\n<li>Patients in which adequate marrow/biopsy specimens can not be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible and must be discussed with the Principal Investigator</li>\n<li>Patients < 21 years of age are eligible if M2 marrow is present with ≤ 25% blasts in marrow after having failed at least 1 course of chemotherapy</li>\n</ul>\n</li>\n<li>Acute lymphoblastic leukemia\n<ul>\n<li>High-risk CR1 [e.g., t(9;22), t(1;19), t(4;11) or other MLL rearrangements, or haplodiploidy]</li>\n<li>Required > 1 course to obtain CR</li>\n<li>In ≥ CR2</li>\n<li>All patients must be in CR as defined by hematologic recovery and < 5% blasts by morphology within the bone marrow and a cellularity of\n<ul>\n<li>15%</li>\n</ul>\n</li>\n<li>Patients in which adequate marrow/biopsy specimens can not be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible and must be discussed with the Principal Investigator</li>\n</ul>\n</li>\n<li>Chronic myelogenous leukemia, excluding refractory blast crisis\n<ul>\n<li>Patients must have failed or be intolerant to imatinib mesylate to be eligible in first chronic phase (CP1)</li>\n</ul>\n</li>\n<li>Advanced myelofibrosis</li>\n<li>MDS in intermediate-2 by International Prognostic Scoring System, high-risk (i.e., refractory anemia with excess blasts [RAEB] or RAEB in transformation), refractory anemia with severe pancytopenia, or high-risk cytogenetics (blasts must be < 10% by a representative bone marrow aspirate morphology)</li>\n<li>Lymphoblastic lymphoma, Burkitt lymphoma, or other high-grade non-Hodgkin lymphoma (NHL) after initial therapy if stage III/IV in partial remission (PR) 1 or after progression if stage I/II < 1 year (stage III/IV patients are eligible after progression in CR/PR)</li>\n<li>Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, or follicular lymphoma that has progressed after at least two different prior therapies\n<ul>\n<li>Patients with bulky disease (nodal mass > 5 cm) should be considered for debulking chemotherapy before transplant</li>\n</ul>\n</li>\n<li>Patients with mantle cell lymphoma or prolymphocytic leukemia are eligible after initial therapy in ≥ CR1 or ≥ PR1</li>\n<li>Large cell NHL > CR2 and > PR2\n<ul>\n<li>Patients in CR2/PR2 with initial short remission (< 6 months) are eligible</li>\n</ul>\n</li>\n<li>Multiple myeloma beyond PR2\n<ul>\n<li>Patients with chromosome 13 abnormalities and first response lasting < 6 months or β-2 microglobulin > 3 mg/L may be eligible after initial therapy</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>No chemotherapy-refractory large cell or high-grade NHL (i.e., progressive disease after > 2 salvage regimens)</li>\n<li>UCB graft matched at 4-6 HLA-A, -B, -DRB1 antigens with the recipient\n<ul>\n<li>May include 0-2 antigen mismatches at the A or B or DRB1 loci</li>\n<li>If 2 UCB units are required to reach the target cell dose, each unit must be a 3-6 HLA-A, -B, -DRB1 antigen match to each other, as well as a 4-6 antigen match to the recipient</li>\n</ul>\n</li>\n</ul>\n PATIENT CHARACTERISTICS:\n<ul>\n<li>Karnofsky performance status (PS) 70-100% (adults) OR Lansky PS 50-100% (children)</li>\n<li>Creatinine < 2.0 mg/dL (adults) OR creatinine clearance > 60 mL/min (children)</li>\n<li>Not pregnant or nursing</li>\n<li>None of the following conditions or diseases:\n<ul>\n<li>Fulminant liver failure</li>\n<li>Cirrhosis with evidence of portal hypertension or bridging fibrosis</li>\n<li>Alcoholic hepatitis</li>\n<li>Esophageal varices</li>\n<li>History of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time</li>\n<li>Ascites related to portal hypertension</li>\n<li>Bacterial or fungal abscess</li>\n<li>Biliary obstruction</li>\n<li>Chronic viral hepatitis with total serum bilirubin > 3 mg/dL</li>\n<li>Symptomatic biliary disease</li>\n</ul>\n</li>\n<li>DLCO corrected > 50% normal</li>\n<li>Left ventricular ejection fraction > 45%</li>\n<li>No uncontrolled viral or bacterial infection at the time of study enrollment</li>\n<li>No active or recent (prior 6 months) invasive fungal infection without Infectious Disease consult and approval</li>\n<li>No history of HIV infection</li>\n</ul>\n PRIOR CONCURRENT THERAPY:\n<ul>\n<li>At least 6 months since prior myeloablative transplantation (patients ≤ 18 years of age)</li>\n<li>No prior myeloablative allotransplantation or autologous transplantation (patients > 18 years of age)</li>\n<li>No more than 12 months since prior extensive alkylator therapy (6 months for alkylator therapy with extensive radiation)</li>\n<li>No prior Y-90 ibritumomab or I-131 tositumomab as part of salvage therapy</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:79283ad5727bf84551b4f8e69168df2c' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:bb181f79c12a7012c1d08c4d0ba6070a' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Acute graft-versus-host disease (GVHD) [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:bb181f79c12a7012c1d08c4d0ba6070a' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:e55fd3e890e97a72bd36275787cc2c3d' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Chronic GVHD [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:e55fd3e890e97a72bd36275787cc2c3d' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:55c4ef8a4ce10f58cf797985f472769a' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Progression-free survival at 1 and 2 years [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:55c4ef8a4ce10f58cf797985f472769a' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:987bb688c8aa246079fb4c2eef5e4c05' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Transplant-related mortality at 6 months [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:987bb688c8aa246079fb4c2eef5e4c05' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:ed2002e7ad4822d38a53047b75a2b412' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Chimerism at multiple time points [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:ed2002e7ad4822d38a53047b75a2b412' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:03de113be77755098579c3c6e2c35fa3' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Neutrophil engraftment at day 42 [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:03de113be77755098579c3c6e2c35fa3' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a41cc9504125ed797290984448cda022' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Platelet recovery at 6 months [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a41cc9504125ed797290984448cda022' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:c3c9dee01578e9bf8309191fe1f3529a' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Clinically significant infections at multiple time points [ Designated as safety issue: Yes ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:c3c9dee01578e9bf8309191fe1f3529a' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:d72258c2b1207c256d46c8b6b2a2e167' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Relapse at 1 and 2 years [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:d72258c2b1207c256d46c8b6b2a2e167' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:5075e7d372c158e19e77e61332bf30ac' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Comparison of single unit UCB transplants with historical controls [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:5075e7d372c158e19e77e61332bf30ac' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:7e95cb9eac1b8088aa20fee161bc1639' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Comparison of single unit UCB transplants with double unit UCB transplants [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:7e95cb9eac1b8088aa20fee161bc1639' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a5051a61889f5d358d21ca58f3b66b24' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It may also stop the patient\'s immune system from rejecting the donor\'s stem cells. The donated stem cells may replace the patient\'s immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body\'s normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor umbilical cord blood transplant works in treating patients with advanced hematological cancer or other disease.\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a5051a61889f5d358d21ca58f3b66b24' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:65f45b87c478a89b211fcc850e7fba8d' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:65f45b87c478a89b211fcc850e7fba8d' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:380e6f4971b6da4c695ccea13830dbd0' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'OBJECTIVES: Primary\n<ul>\n<li>To estimate the probability of survival at 1 year in patients with advanced hematological malignancies or other diseases treated with non-myeloablative unrelated donor umbilical cord blood transplantation.</li>\n</ul>\n Secondary\n<ul>\n<li>Six Month non-relapse mortality.</li>\n<li>Chimerism at days 7, 14, 21, 28, 56, and 80, at 6 months, and at 1 and 2 years.</li>\n<li>To determine the incidence of neutrophil engraftment at day 42.</li>\n<li>To determine the incidence of platelet engraftment at 6 months.</li>\n<li>To determine the incidence of grade II-IV and III-IV acute graft-versus-host-disease (GVHD) at day 100.</li>\n<li>To determine the incidence of chronic GVHD at 1 year.</li>\n<li>To determine the incidence of clinically significant infections at 6 months and at 1 and 2 years.</li>\n<li>To determine the probability of progression-free survival at 1 and 2 years.</li>\n<li>To determine the probability of survival at 2 years.</li>\n<li>To determine the incidence of relapse or disease progression at 1 and 2 years.</li>\n</ul>\n OUTLINE: This is a multicenter study. Patients are stratified according to disease status and prior therapy (hematologic malignancy or other disease that was treated with an autologous stem cell transplant or ≥ 2 courses of multiagent chemotherapy within the past 3 months vs hematologic malignancy or other disease that was treated with an autologous stem cell transplant > 12 months ago or with ≤ 1 course of multiagent chemotherapy or immunosuppressive chemotherapy within the past 3 months vs refractory leukemia or lymphoma for which patient was rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy).\n<ul>\n<li>Conditioning regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV on day -6. Patients also undergo total body irradiation on day -1. Some patients also receive anti-thymocyte globulin IV on days -6 to -4.</li>\n<li>Umbilical cord blood transplantation (UCBT): Patients undergo UCBT on day 0.</li>\n<li>Immunosuppressive therapy (graft-versus-host disease prophylaxis): Patients receive cyclosporine IV over 1 hour or orally (as tolerated) every 8 or 12 hours beginning on day -3 and continuing for approximately 6 months. Patients also receive mycophenolate mofetil IV every 8 hours on days -3 to 5 and then orally on days 6-30. After completion of study treatment, patients are followed at 6 months and then annually thereafter.</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:380e6f4971b6da4c695ccea13830dbd0' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:6fe800b4b5eebda623c7d8c868883582' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'DISEASE CHARACTERISTICS:\n<ul>\n<li>Diagnosis of advanced hematologic malignancy or other disease not curable by conventional chemotherapy, including any of the following:\n<ul>\n<li>Acute myeloid leukemia in complete remission (CR)* (as defined by hematologic recovery, < 5% blasts in the bone marrow by morphology, and a cellularity of > 15%), meeting one of the following criteria:\n<ul>\n<li>In first complete remission (CR1) AND has high-risk disease as evidenced by any of the following:\n<ul>\n<li>Preceding myelodysplastic syndromes (MDS)</li>\n<li>High-risk cytogenetics (e.g., monosomy 5 or 7, or as defined by referring institution treatment protocol)</li>\n<li>Required > 2 courses of therapy to obtain CR</li>\n<li>Erythroblastic or megakaryocytic leukemia</li>\n</ul>\n</li>\n<li>In second CR (CR2) or beyond</li>\n</ul>\n</li>\n<li>Acute lymphoblastic leukemia in CR* (as defined by hematologic recovery, < 5% blasts in the bone marrow by morphology, and a cellularity of > 15%), meeting one of the following criteria:\n<ul>\n<li>In CR1 AND has high-risk disease as evidenced by any of the following:\n<ul>\n<li>t(9;22), t(1;19), t(4;11), or other MLL rearrangements</li>\n<li>Hyplodiploid</li>\n<li>Required > 1 course of therapy to obtain CR</li>\n</ul>\n</li>\n<li>Beyond CR2</li>\n</ul>\n</li>\n<li>Chronic myelogenous leukemia (CML)\n<ul>\n<li>All types are allowed (except refractory blast crisis CML)</li>\n<li>Patients in chronic phase CML must have failed or been intolerant to prior imatinib mesylate (Gleevec) or other tyrosine kinase inhibitors</li>\n</ul>\n</li>\n<li>MDS\n<ul>\n<li>Any subtype allowed (including refractory anemia [RA])</li>\n<li>Severe pancytopenia or complex cytogenetics</li>\n<li>Blasts must be < 5% (if blasts are ≥ 5%, pre-transplant induction therapy is required to reduce blast count to < 5%)</li>\n</ul>\n</li>\n<li>Large cell lymphoma, Hodgkin lymphoma, or multiple myeloma, meeting one of the following criteria:\n<ul>\n<li>Chemotherapy-sensitive disease that has failed prior therapy\n<ul>\n<li>Patients with large cell lymphoma or Hodgkin lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky)</li>\n</ul>\n</li>\n<li>Ineligible for an autologous stem cell transplant</li>\n</ul>\n</li>\n<li>Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, or follicular lymphoma that has progressed after ≥ 2 prior therapies\n<ul>\n<li>Patients with bulky disease should be considered for debulking chemotherapy prior to transplant</li>\n<li>Patients with refractory disease are eligible provided disease is non-bulky AND an estimated tumor doubling time is ≥ 1 month</li>\n</ul>\n</li>\n<li>Lymphoplasmacytic lymphoma, mantle cell lymphoma, or prolymphocytic leukemia\n<ul>\n<li>Chemotherapy-sensitive disease that was previously treated with initial therapy\n<ul>\n<li>Patients with mantle cell lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky)</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Mycosis fungoides and Sezary syndrome</li>\n<li>Bone marrow failure syndromes, except for Fanconi anemia</li>\n<li>Myeloproliferative syndromes NOTE: *Patients for whom adequate marrow/biopsy specimens can not be obtained to determine remission status by morphologic assessment must have fulfilled criteria of remission (< 5% blasts by flow cytometry and recovery of peripheral blood counts with no circulating blasts)</li>\n</ul>\n</li>\n<li>Ineligible for autologous stem cell transplant due to any of the following:\n<ul>\n<li>Prior autologous stem cell transplant</li>\n<li>Inadequate autologous stem cell harvest</li>\n<li>Inability to withstand a myeloablative preparative regimen</li>\n<li>Clinically aggressive/high-risk disease</li>\n</ul>\n</li>\n<li>No evidence of progressive disease by imaging modalities or biopsy (persistent PET scan activity allowed provided there are no CT scan changes indicating progression)</li>\n<li>Acute leukemia that is refractory, persistent, or relapsed (defined as > 5% blasts in normocellular bone marrow) allowed provided patient was rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy</li>\n<li>Patients with stable disease are eligible provided the largest residual nodal mass is approximately < 5 cm (largest residual mass must represent a 50% reduction and be approximately < 7.5 cm for patients who have responded to prior therapy)</li>\n<li>No active CNS malignancy</li>\n<li>Umbilical cord blood (UCB) donor available\n<ul>\n<li>UCB graft matched at 4/6 HLA-A, -B, and -DRB1 antigens with the recipient\n<ul>\n<li>May include 0-2 antigen mismatches at the A, B, or DRB1 loci</li>\n<li>Unit selection based on cryopreserved nucleated cell dose and HLA-A, -B, and -DRB1 using intermediate resolution A, B antigen and DRB1 allele typing</li>\n</ul>\n</li>\n<li>If 2 UCB units are required to reach the target cell dose, each unit must be a 3/6 HLA-A, -B, and -DRB1 antigen match to each other, as well as a 4/6 antigen match to the recipient</li>\n<li>No 5-6/6 HLA-A, -B, and -DRB1 matched sibling donor available</li>\n</ul>\n</li>\n</ul>\n PATIENT CHARACTERISTICS:\n<ul>\n<li>Karnofsky performance status (PS) 60-100% OR Lansky PS 50-100%</li>\n<li>Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance > 40 mL/min (pediatrics)\n<ul>\n<li>Adult patients with a creatinine > 1.2 mg/dL or a history of renal dysfunction must have an estimated creatinine clearance of > 40 mL/min</li>\n</ul>\n</li>\n<li>Not pregnant or nursing</li>\n<li>Negative pregnancy test</li>\n<li>LVEF ≥ 35%</li>\n<li>DLCO > 30% predicted</li>\n<li>No requirement for O_2</li>\n<li>No decompensated congestive heart failure</li>\n<li>No uncontrolled arrhythmia</li>\n<li>None of the following liver diseases or conditions:\n<ul>\n<li>Fulminant liver failure</li>\n<li>Cirrhosis with evidence of portal hypertension or bridging fibrosis</li>\n<li>Alcoholic hepatitis</li>\n<li>Esophageal varices</li>\n<li>History of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time</li>\n<li>Ascites related to portal hypertension</li>\n<li>Bacterial or fungal abscess</li>\n<li>Biliary obstruction</li>\n<li>Chronic viral hepatitis with total serum bilirubin > 3 mg/dL</li>\n<li>Symptomatic biliary disease</li>\n</ul>\n</li>\n<li>Recent mold infection (e.g., Aspergillus) allowed provided patient received ≥ 30 days of appropriate treatment AND infection is controlled and cleared by Infectious Disease</li>\n<li>No evidence of HIV infection or known HIV-positive serology</li>\n<li>No uncontrolled viral or bacterial infection</li>\n</ul>\n PRIOR CONCURRENT THERAPY:\n<ul>\n<li>See Disease Characteristics</li>\n<li>At least 3 months since prior myeloablative stem cell transplantation</li>\n</ul>\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:6fe800b4b5eebda623c7d8c868883582' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:6777cd025297ed91beb81e60e527b3b6' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Probability of survival at 2 years [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:6777cd025297ed91beb81e60e527b3b6' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a5a90269f9ea8d1bca2ea1136943f856' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of non-relapse mortality at 6 months [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:a5a90269f9ea8d1bca2ea1136943f856' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:6c5a4fbe135086479d355ba174ba23fb' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Chimerism at days 7, 14, 21, 28, 56, and 80, at 6 months, and at 1 and 2 years [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:6c5a4fbe135086479d355ba174ba23fb' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:64f23d334170300081e62e2d0606d149' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of neutrophil engraftment at day 42 [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:64f23d334170300081e62e2d0606d149' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:8da0af707c295dfd9ab28dc1335078e5' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of platelet engraftment at 6 months [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:8da0af707c295dfd9ab28dc1335078e5' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:6c00b649ce50e4c24929e434b5fe2ef1' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of acute graft-versus-host-disease (GVHD) at day 100 and extensive chronic GVHD at 1 year [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:6c00b649ce50e4c24929e434b5fe2ef1' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:40394b0d9c9a3d1fa9be28125ce62293' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of clinically significant infections at 6 months and at 1 and 2 years [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:40394b0d9c9a3d1fa9be28125ce62293' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:9e2eee4653b7cfdb1e2c3609a6fd2029' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Probability of progression-free survival at 1 and 2 years [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:9e2eee4653b7cfdb1e2c3609a6fd2029' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:5ed11b27ca09fefbe28a71afc8e52f6c' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = 'Incidence of relapse at 1 and 2 years [ Designated as safety issue: No ]\n', created = 1283572458, expire = 1283658858, headers = '', serialized = 0 WHERE cid = '1:5ed11b27ca09fefbe28a71afc8e52f6c' in /persistent/html/includes/cache.inc on line 109.

Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant

Trial phase:

Phase II

Recruitment status:

Not yet recruiting

RATIONALE: Palifermin may help relieve or prevent oral mucositis caused by chemotherapy and radiation therapy in young patients undergoing stem cell transplant. PURPOSE: This randomized phase II trial is studying palifermin to see how well it works compared with a placebo in preventing oral mucositis caused by chemotherapy and/or radiation therapy in young patients undergoing stem cell transplant.

Background information

Trial ID:

NCT00728585

Other unique IDs:

CDR0000588622

COG-ACCL0521

Official title:

A Group-Wide Double-Blind Randomized Placebo-Controlled Trial of Palifermin to Prevent Chemotherapy and/or Radiotherapy Induced Oral Mucositis in Children Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

Detailed description:

OBJECTIVES: Primary

To compare whether palifermin versus placebo administered to pediatric patients three days prior to conditioning and three days after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) is associated with a reduction in the incidence of WHO grade 3 or 4 oral mucositis.

Number to be enrolled:

200 patients

Lenalidomide, Fludarabine, and Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Therapy

Trial phase:

Phase I

Recruitment status:

Recruiting

RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with fludarabine and cyclophosphamide may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with fludarabine and cyclophosphamide and to see how well they work in treating patients with advanced chronic lymphocytic leukemia that did not respond to previous therapy.

Background information

Trial ID:

NCT00727415

Other unique IDs:

CDR0000599893

GIMEMA-LLC0606

EUDRACT-2006-006185-42

EU-20865

Official title:

A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients.

Detailed description:

OBJECTIVES: Primary

To determine the maximum tolerated dose (MTD) of lenalidomide when administered with fludarabine and cyclophosphamide in patients with advanced relapsed or refractory chronic lymphocytic leukemia. (Phase I)
To evaluate the complete response (CR) rate in patients treated with lenalidomide (at the MTD) in combination with fludarabine and cyclophosphamide.

Number to be enrolled:

52 patients

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Recruitment status:

Recruiting

RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer.

Background information

Trial ID:

NCT00726830

Other unique IDs:

CDR0000598283

MDA-2007-0791

Official title:

A Randomized Comparison of Oral Methadone as a "First-Switch" Opioid Versus Opioid Switching Between Sustained-Release Morphine and Oxycodone for Oncology-Hematology Outpatients With Pain Management Problems: The "Simply Rotate" Study

Detailed description:

OBJECTIVES: Primary

To compare the effectiveness of an opioid rotation to oral methadone versus an opioid rotation to another long-acting strong opioid (sustained-release morphine or oxycodone) in controlling pain (i.e., analgesia) in patients with cancer.

Number to be enrolled:

300 patients

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Trial phase:

Phase I

Recruitment status:

Recruiting

RATIONALE: A donor peripheral stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them. Giving an infusion of donor T cells may helps stop the patient's immune system from rejecting the donor's stem cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of donor T cells in treating patients with high-risk hematologic cancer who are undergoing donor peripheral blood stem cell transplant.

Background information

Trial ID:

NCT00725062

Other unique IDs:

CDR0000601051

UMN-2004LS034

MT2004-03

Official title:

MT2004-03: A Clinical Trial of Adult CD4+ CD25+ Regulatory T Cells in BMT Recipients Was "A Dose Escalation Study of CD4+ CD25+ Cells in Adult Patients Undergoing HLA-Identical Sibling Donor Peripheral Blood Progenitor Cell (PBPC) Transplantation&quo

Detailed description:

OBJECTIVES: Primary

To determine whether CD4- and CD25-positive regulatory T cells can be safely administered to patients with high-risk hematologic malignancies undergoing HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation.

Secondary

To determine the incidence of grade II-IV acute graft-versus-host-disease (GVHD), chronic GVHD, relapse, and survival after administration of CD4- and CD25-positive regulatory T cells in these patients.

Number to be enrolled:

32 patients

Clofarabine Bone Marrow Cytoreduction

Recruitment status:

Recruiting

For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant related mortality.

Background information

Trial ID:

NCT00724009

Other unique IDs:

15809B

Official title:

Clofarabine Bone Marrow Cytoreduction : Feasibility of Induction as a Bridge to Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Acute Leukemias, Myelodysplastic Syndromes, and Advanced Myeloproliferative Diseases.

Detailed description:

Screening will be done prior to enrollment in the study. The following will be done as part of the screening process:

Medical history review
Physical exam
Measurement of vital Signs
Blood tests (approximately 6 teaspoons of blood) will be done to see if the liver and kidneys are healthy, HIV (the virus that causes AIDS) test for this study and pregnancy test.
Urine test
Bone marrow biopsy and aspirate

Number to be enrolled:

27 patients

Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Trial phase:

Phase II

Recruitment status:

Recruiting

RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in treating patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.

Background information

Trial ID:

NCT00723203

Other unique IDs:

CDR0000601203

CHNMC-07174

NOVARTIS-CHNMC-07174

Official title:

A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60

Detailed description:

OBJECTIVES: Primary

To determine the antitumor activity of panobinostat, in terms of objective response rate, time to progression, and survival, in patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.
To assess the toxicity of panobinostat in these patients.

Secondary

To perform correlative laboratory studies to assess changes in various proteins that may be altered by histone deacetylase inhibition therapy.

Number to be enrolled:

74 patients

Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Trial phase:

Phase II

Recruitment status:

Recruiting

RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from an unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well umbilical cord blood transplant from an unrelated donor works in treating patients with hematologic cancer.

Background information

Trial ID:

NCT00723099

Other unique IDs:

CDR0000600343

FHCRC-2239.00

FHCRC-IR-6722

Official title:

Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen

Detailed description:

OBJECTIVES: Primary

To estimate probability of 1-year survival of patients with hematological malignancies undergoing a reduced-intensity preparative regimen during unrelated donor umbilical cord blood transplantation.
To demonstrate equivalent or improved engraftment rates with a nonanti-thymocyte-based conditioning regimen in patients who have not received recent chemotherapy (stratum 2).

Number to be enrolled:

60 patients

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

RATIONALE: Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia.

Background information

Other unique IDs:

CDR0000600217

COG-AALL0622

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Trial phase:

Phase II

Recruitment status:

Recruiting

RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well umbilical cord blood transplant given together with cyclophosphamide, fludarabine, and total-body irradiation works in treating patients with hematologic disease.

Background information

Trial ID:

NCT00719888

Other unique IDs:

CDR0000597644

FHCRC-2010.00

Official title:

Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen

Detailed description:

OBJECTIVES: Primary

The 1-year survival of patients with hematological malignancies undergoing umbilical cord blood transplantation after a myeloablative preparative regimen comprising of cyclophosphamide, fludarabine, and fractionated total-body irradiation.

Number to be enrolled:

60 patients

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Trial phase:

Phase II

Recruitment status:

Active, not recruiting

RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor umbilical cord blood transplant works in treating patients with advanced hematological cancer or other disease.

Background information

Trial ID:

NCT00719849

Other unique IDs:

CDR0000597623

FHCRC-2012.00

Official title:

Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen

Detailed description:

OBJECTIVES: Primary

To estimate the probability of survival at 1 year in patients with advanced hematological malignancies or other diseases treated with non-myeloablative unrelated donor umbilical cord blood transplantation.

Number to be enrolled:

60 patients

Search clinical trials

Leukemia

Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant

Lenalidomide, Fludarabine, and Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Therapy

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Clofarabine Bone Marrow Cytoreduction

Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Conditions

Clinical trial sponsors

User login

Study design